Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium
hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with
mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between
mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no
significant differences were seen. These data support extrapolation of this finding to all antacids
because the reduction in exposure when mycophenolate mofetil was co-administered with magnesium
and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered
with PPIs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium
hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with
mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between
mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no
significant differences were seen. These data support extrapolation of this finding to all antacids
because the reduction in exposure when mycophenolate mofetil was co-administered with magnesium
and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered
with PPIs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium
hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with
mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between
mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no
significant differences were seen. These data support extrapolation of this finding to all antacids
because the reduction in exposure when mycophenolate mofetil was co-administered with magnesium
and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered
with PPIs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 38a6790d989fb2086bcd78166cdb9ac1029b47140afbab4f00aac9bf32a351b5 · Zeichen 698–1373 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.